VNDA · Company research
Vanda Pharmaceuticals Inc. (VNDA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits | VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug Stocktwits | View source ↗ | Stocktwits | Oct 17, 2026 | neutral | 0 | 0.6 |
| Vanda Pharmaceuticals: Cash Is Running Out Faster Than The Launches (NASDAQ:VNDA) - Seeking Alpha | Vanda Pharmaceuticals: Cash Is Running Out Faster Than The Launches (NASDAQ:VNDA) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 15, 2026 | neutral | 0 | 0.6 |
| XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? | Xenon Pharmaceuticals paused enrollment in phase III depression trials for azetukalner after unexpected neurological and psychiatric side effects emerged, including confusion, speech difficulties, and psychosis cases. The company is reviewing dose adjustments with top-line results expected in Q1 2027. However, Xenon's epilepsy program remains promising, with an FDA application pending for focal onset seizures treatment, offering potential growth opportunities despite the depression program setback. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bearish | -0.333 | 1 |
| XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? | Xenon Pharmaceuticals paused enrollment in phase III depression trials for azetukalner after unexpected neurological and psychiatric side effects emerged, including confusion, speech difficulties, and psychosis cases. The company is reviewing dose adjustments with top-line results expected in Q1 2027. However, Xenon's epilepsy program remains promising, with an FDA application pending for focal onset seizures treatment, offering potential growth opportunities despite the depression program setback. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bearish | -0.333 | 1 |
| Vanda Pharmaceuticals (VNDA) Shares Fall 2% Premarket After Phas - GuruFocus | Vanda Pharmaceuticals (VNDA) Shares Fall 2% Premarket After Phas GuruFocus | View source ↗ | GuruFocus | Oct 15, 2026 | neutral | 0 | 0.6 |
| VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug - Stocktwits | VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug Stocktwits | View source ↗ | Stocktwits | Oct 15, 2026 | neutral | 0 | 0.6 |
| Vanda Pharmaceuticals stock falls after anxiety drug trial fails - Yahoo Finance | Vanda Pharmaceuticals stock falls after anxiety drug trial fails Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| A social anxiety drug missed its main goal. Its maker put the program on hold pending analysis. - Stock Titan | A social anxiety drug missed its main goal. Its maker put the program on hold pending analysis. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits | VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits | Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits | Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| Three parties report a shared stake with no sole voting power in Vanda Pharmaceuticals (VNDA). - Stock Titan | Three parties report a shared stake with no sole voting power in Vanda Pharmaceuticals (VNDA). Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Three posters examine a treatment for a rare form of psoriasis - Stock Titan | Three posters examine a treatment for a rare form of psoriasis Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Vanda Pharmaceuticals (VNDA) Stock Holds Steady As Losses Deepen - Simply Wall Street | Vanda Pharmaceuticals (VNDA) Stock Holds Steady As Losses Deepen Simply Wall Street | View source ↗ | Simply Wall Street | Aug 7, 2026 | neutral | 0 | 0.6 |
| Insider Sellers Might Regret Selling Vanda Pharmaceuticals Shares at a Lower Price Than Current Market Value - Simply Wall Street | Insider Sellers Might Regret Selling Vanda Pharmaceuticals Shares at a Lower Price Than Current Market Value Simply Wall Street | View source ↗ | Simply Wall Street | Jul 16, 2026 | neutral | 0 | 0.6 |
| 47 years since the last new motion-sickness treatment, NEREUS will sponsor IndyCar - Stock Titan | 47 years since the last new motion-sickness treatment, NEREUS will sponsor IndyCar Stock Titan | View source ↗ | Stock Titan | Jul 15, 2026 | neutral | 0 | 0.6 |
| VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy - Yahoo Finance | VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy Yahoo Finance | View source ↗ | Yahoo Finance | Jul 7, 2026 | neutral | 0 | 0.6 |
| VNDA Forecast — Price Target — Prediction for 2027 - TradingView | VNDA Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus - Yahoo Finance | How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus Yahoo Finance | View source ↗ | Yahoo Finance | May 17, 2026 | neutral | 0 | 0.6 |
| Vanda Pharmaceuticals (VNDA) Stock Falls on Q4 2025 Earnings - Quiver Quantitative | Vanda Pharmaceuticals (VNDA) Stock Falls on Q4 2025 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | Feb 11, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.